Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Kiniksa Pharmaceuticals International Plc shares valued at $1,928,596 were purchased by KIMBERLY J. POPOVITS on Jul 30 ’25. At $29.90 per share, KIMBERLY J. POPOVITS acquired 64,508 shares.
Also, Tessari Eben sold 18,900 shares, netting a total of over 542,808 in proceeds. Following the sale of shares at $28.72 each, the insider now holds 49,163 shares.
Before that, Tessari Eben had added 18,900 shares to its account. In a trade valued at $542,860, the Officer bought Kiniksa Pharmaceuticals International Plc shares for $28.72 each.
As published in their initiating research note from Citigroup on March 13, 2025, Kiniksa Pharmaceuticals International Plc [KNSA] has been a Buy and the price target has been revised to $40. Analysts at Jefferies started covering the stock with ‘”a Buy”‘ outlook in a report released in mid September. As of May 03, 2024, Wells Fargo has initiated its “an Overweight” rating for KNSA. Earlier on June 29, 2020, BofA Securities resumed its rating. Their recommendation was “a Buy” for KNSA stock.
Analyzing KNSA Stock Performance
On last trading session, Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] rose 0.67% to $30.26. The stock’s lowest price that day was $29.9, but it reached a high of $30.83 in the same session. During the last five days, there has been a surge of approximately 12.49%. Over the course of the year, Kiniksa Pharmaceuticals International Plc shares have jumped approximately 15.76%.
Support And Resistance Levels for Kiniksa Pharmaceuticals International Plc (KNSA)
RSI (Relative Strength Index) is 61.36 on the 14-day chart, showing neutral technical sentiment.
Is Kiniksa Pharmaceuticals International Plc subject to short interest?
Stocks of Kiniksa Pharmaceuticals International Plc saw a sharp rise in short interest on 2025-07-15 jumping by 0.17 million shares to 2.53 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 2.36 million shares. A jump of 6.89% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.48 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.48.
Which companies own the most shares of Kiniksa Pharmaceuticals International Plc (KNSA)?
In terms of Kiniksa Pharmaceuticals International Plc share price expectations, FactSet research, analysts set an average price target of 54 in the next 12 months, up nearly 79.64% from the previous closing price of $30.06. Analysts anticipate Kiniksa Pharmaceuticals International Plc stock to reach 54 by 2025, with the lowest price target being 54. In spite of this, 1 analysts ranked Kiniksa Pharmaceuticals International Plc stock as Buy at the end of 2025. On April 01, 2020, BofA/Merrill assigned a price target of “a Buy” to the stock and initiated coverage with a $25.
